Some of them use EPHX2 inhibitors such as GSK2256294, EC5026, and AR9281 to treat conditions such as insulin resistance (NCT03486223), neuroinflammation at subarachnoid hemorrhage (NCT03318783), neuropathic pain after spinal cord injury (NCT06438471), vasoconstriction in heat failure (NCT00654966), hypertension and impaired glucose tolerance (NCT00847899), and vulnerable patients such as those with obesity, smoking, older age, or depression (NCT01762774, NCT02006537, NCT05575713). This evidence concerns the gene EPHX2 and subarachnoid hemorrhage.